Skip to main content

Janus Henderson Investors — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

227
Companies
$35.8B
Total invested
$153.6M
Avg. check
23
Industries
Biotechnology 21Medical 11Life Science 11Therapeutics 10Health Care 9Biopharma 5+17 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121144 of 227
Thrive Earlier Detection
January 2023

Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.

Biotechnology · CambridgeVenture - Series Unknown
Shoreline Biosciences
November 2021

Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients.

Biotechnology · La Jolla$140.0M Series B
Nuvalent
November 2025

Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.

Biotechnology · Cambridge$500.0M Post-IPO Secondary
Metsera
November 2024

Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.

Biopharma · New York$215.0M Series B
Centessa Pharmaceuticals
November 2025

Centessa Pharmaceuticals is a pharmaceutical company that focuses on drug development to address significant medical needs.

Biotechnology · Cambridge$250.0M Post-IPO Equity
Biomea Fusion
October 2025

Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.

Biotechnology · Redwood City$25.0M Post-IPO Equity
Cedilla Therapeutics
October 2021

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

Biotechnology · Cambridge$25.0M Series B
Alpha-9 Oncology
October 2024

Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

Biotechnology · Vancouver$175.0M Series C
Owlet Baby Care
October 2025

Owlet Baby Care offers a health monitor that allows parents to view their child's vital signs in real-time.

Baby · Lehi$30.0M Post-IPO Equity
Disc Medicine
October 2025

Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.

Biotechnology · Watertown$225.0M Post-IPO Equity
Dice Therapeutics
October 2022

Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.

Biotechnology · San Francisco$345.0M Post-IPO Equity
AtaiBeckley
October 2025

AtaiBeckley develops innovative mental health treatments that address significant unmet medical needs.

Biotechnology · Berlin$149.5M Post-IPO Equity
C4 Therapeutics
October 2025

C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.

Biotechnology · Cambridge$125.0M Post-IPO Equity
LEXEO Therapeutics
October 2025

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Biotechnology · New York$154.0M Post-IPO Equity
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post Ipo Equity
Longeveron
March 2026

Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.

Biotechnology · Miami$30.0M Post Ipo Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post Ipo Equity
Bicara Therapeutics
February 2026

Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.

Biopharma · Cambridge$150.0M Post Ipo Equity
Immunic Therapeutics
February 2026

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Biotechnology · New York$400.0M Post Ipo Equity
Third Arc Bio
February 2026

Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.

Biotechnology · Boston$52.0M Series A
CesiumAstro
February 2026

CesiumAstro provides out-of-the-box communication systems for satellites, UAVs, launch vehicles, and other space or airborne platforms.

Aerospace · Austin$270.0M Series C
Vaxcyte
January 2026

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Biopharma · San Carlos$632.5M Post Ipo Equity
Tenpoint Therapeutics
January 2026

Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

Biotechnology · Camborne$150.0M Debt Financing
TRex Bio
January 2026

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

Bioinformatics · South San Francisco$50.0M Series Unknown

Where Janus Henderson Investors invests

Biotechnology21
Medical11
Life Science11
Therapeutics10
Health Care9
Biopharma5

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?

Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?

Janus Henderson Investors's top investment sectors include Biotechnology, Medical, Life Science, Therapeutics, Health Care. The firm invests across 23 different industry categories.

What is Janus Henderson Investors's largest investment?

Among tracked funding rounds, Vaxcyte received $632.5M in a Post Ipo Equity round. Janus Henderson Investors's total known invested capital is $35.8B.

What is the average investment size for Janus Henderson Investors?

Janus Henderson Investors's average investment size is $153.6M across its portfolio of 227 companies.

What are Janus Henderson Investors's most recent investments?

Recent Janus Henderson Investors portfolio additions include Thrive Earlier Detection, Shoreline Biosciences, Nuvalent, Metsera, Centessa Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 227 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →